At the annual meeting of the American Association of Cancer Researchers, presenters discuss strategies to improve the safety and effectiveness of reengineered T cells in eradicating tumors.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
Krishan Maggon 's curator insight,
April 21, 2015 7:56 AM
Meditope Biosciences' SnAP - Site-specific, novel Antibody Platform—technology is carving a new space in antibody design by turning antibodies into a "Lego-like" piece that can be combined with other pieces to expand functionality by easily 'snapping' anything imaginable on to (or off of) an antibody. |
CAR T Cell immunotherapy, TIL, ATC, TCR unpredictable toxicity at AACR 2015